Novo Nordisk A/SNOV
▲ ポジティブ需要関連度
Novo Nordisk remains a leader in diabetes and weight loss markets with advancing candidates and diversification into rare blood diseases.
銘柄への影響 4
Biotech & Genomic Medicine
Novo Nordisk A/S
Pfizer IncPFE
▲ ポジティブ資本関連度
Pfizer offers a high forward dividend yield of 7.1% and is expected to benefit from products like Padcev and Abrysvo, along with a promising pipeline.
Regeneron Pharmaceuticals IncREGN
言及
Health Care
Sanofi SASAN
▲ ポジティブ需要関連度
Sanofi is driven by strong Dupixent performance and pipeline prospects like frexalimab with potential peak sales over $1 billion.